Summary & Overview

CPT 81542: mRNA 22-Gene Expression Profiling and Prostate Cancer Risk Score

Headline: CPT code 81542: Laboratory mRNA 22-Gene Profiling and Algorithmic Risk Score for Prostate Cancer

CPT code 81542 represents a molecular diagnostic laboratory service that performs mRNA expression profiling for 22 genes and uses an algorithmic analysis combining test results with patient data to report a risk score for prostate cancer metastasis. This code matters nationally as genomic risk stratification increasingly informs prostate cancer prognosis, treatment planning, and discussions about adjuvant therapy and surveillance.

Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, typical sites of service, and the payer landscape relevant to coverage and implementation. The publication summarizes available benchmarks, coding and billing considerations, and clinical context for how a 22-gene mRNA risk score is used in prostate cancer management. Data not provided in the input—such as specific coverage policies, associated ICD-10 diagnoses, and related codes—are noted as unavailable. The report is intended for a national audience of clinicians, laboratory directors, and billing professionals seeking a clear summary of what CPT code 81542 denotes and where it fits in clinical and payer workflows.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareCPT 81542molecular diagnosticsprostate cancergene expression profilingmRNArisk scorelaboratory testingprecision medicine

Billing Code Overview

CPT code 81542 describes a laboratory service in which the lab analyst performs technical mRNA gene expression profiling of 22 genes and applies an algorithmic analysis that integrates the laboratory results with patient data to report a risk score for prostate cancer metastasis. The service type is molecular diagnostic testing with algorithmic risk reporting.

The typical site of service for CPT code 81542 is a clinical molecular diagnostic laboratory or reference laboratory, with results used by treating clinicians to inform prognosis and potential management for patients with prostate cancer.

Clinical & Coding Specifications

Clinical Context

A 66-year-old man with newly diagnosed, localized prostate adenocarcinoma (Gleason score 7 [3+4], PSA 8.4 ng/mL, clinical stage T1c–T2a) undergoes definitive diagnostic workup to inform adjuvant treatment decisions. After prostate biopsy confirms cancer, the clinician orders an mRNA gene expression profiling test to assess risk of metastatic progression. A preserved biopsy specimen is sent to a certified molecular laboratory. The laboratory analyst performs technical extraction, quantifies expression of 22 genes, and runs the proprietary algorithm combining assay results with clinical inputs (for example, Gleason pattern, PSA, margin status) to generate a numeric risk score for prostate cancer metastasis. The final report is returned to the ordering urologist or oncologist, who integrates the risk score into multidisciplinary care planning. Typical site of service is an independent clinical molecular laboratory or hospital-based pathology/molecular lab; specimen collection occurs in an outpatient clinic or ambulatory surgical center during biopsy, and analysis occurs in the laboratory facility.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the professional interpretation/analysis component of the test when separated from the technical component.
`TC`	Technical component	Use when billing only the laboratory technical component (processing and testing) separate from professional interpretation.
`59`	Data not available in the input.	Data not available in the input.
`52`	Reduced services	Use when the laboratory test is partially performed or truncated resulting in reduced service.
`53`	Discontinued service	Use when testing is started but discontinued due to unexpected events (e.g., insufficient specimen) and the payer allows partial payment.
`62`	Two surgeons	Use when two qualified providers share primary responsibility for a single service; rarely applies but included where dual coverage of interpretation occurs.
`78`	Unplanned return to the operating/procedure room by the same physician following initial procedure	Use only if a specimen is obtained during an unplanned return and separate billing is justified.
`80`	Assistant surgeon	Use when an assistant surgeon provides services during the specimen collection/procedure and billing requires this modifier.
`82`	Assistant (when qualified resident surgeon not available)	Use when an assistant is required and a qualified resident is not available.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant-at-surgery	Use when an advanced practice clinician serves as assistant-at-surgery in specimen procurement and payer accepts modifier.
`QK`	Medical direction of two, three, or four individuals performing services	Use when a physician directs multiple non-physician providers involved in specimen processing/collection.
`QX`	Modifier contingent upon `QK`	Use when a non-physician practitioner performs services under medical direction as specified by `QK`.
`QY`	Service furnished by a registered nurse anesthetist under medical direction	Typically not applicable to the lab test itself; include only if anesthesia services are billed with specimen collection.
`11`	Office or other outpatient visit by the physician for evaluation and management	Use when the professional interpretation is billed in conjunction with an outpatient E/M visit and payer requires modifier to clarify.

Taxonomy Code	Specialty	Notes
207P00000X	Urology	Ordering and interpreting clinicians; urologists commonly order prognostic genomic assays for prostate cancer.
208800000X	Medical Oncology	Medical oncologists use risk scores to guide adjuvant therapy decisions.
207K00000X	Pathology	Pathologists and molecular pathologists perform or oversee laboratory testing and reporting.
363L00000X	Clinical Laboratory	Laboratory directors and clinical laboratory specialists manage assay performance and reporting.
367A00000X	Molecular Genetics	Molecular geneticists and laboratory scientists responsible for test development and algorithm validation.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C61`	Malignant neoplasm of prostate	Primary diagnosis indicating prostate cancer; the test evaluates risk of metastasis for management decisions.
`D07.5`	Carcinoma in situ of prostate	Used rarely; may be relevant when atypical or early lesions prompt additional prognostic assessment.
`R97.20`	Elevated prostate specific antigen [PSA] without diagnosis of prostate cancer	Elevated PSA often triggers biopsy and subsequent molecular testing for risk stratification after cancer is confirmed.
`N40`	Benign prostatic hyperplasia	Common comorbidity impacting clinical context; differential diagnosis prior to biopsy and may be present in patients undergoing testing.
`Z85.46`	Personal history of malignant neoplasm of prostate	Used in surveillance contexts where molecular profiling may inform risk of recurrence or progression.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`88305`	Level IV surgical pathology, gross and microscopic exam	Commonly billed for initial pathologic evaluation of biopsy tissue used to confirm prostate cancer and prepare material for molecular testing.
`89240`	Molecular pathology procedure, extraction and preparation of nucleic acids (if applicable)	Billed when specific laboratory extraction procedures are reported separately; may be part of the technical workflow supporting the gene expression assay.
`84999`	Unlisted clinical pathology procedure	Occasionally used for novel or proprietary molecular assays when no specific CPT exists; however, `81542` is the specific reported code for this mRNA expression test.
`88342`	Immunohistochemistry (per specimen)	May be performed on biopsy tissue as ancillary testing to characterize tumor and support risk assessment alongside gene expression profiling.
`81210`	BRCA1 gene analysis (example hereditary testing)	While not directly related to prostate metastasis profiling, other genetic tests may be ordered in the oncologic workup; included here as an example of complementary genetic testing services.